Value through Innovation23 July 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

09.06.2012

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

- EX US & UK. Medical Media Only.
09.06.2012

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

- EX US & UK. Medical Media Only.
09.06.2012

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

- EX US & UK. Medical Media Only.
06.06.2012

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only
05.06.2012

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.
04.06.2012

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only
01.06.2012

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only
31.05.2012

Boehringer Ingelheim expands development capacities with new technical centre

30.05.2012

Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines

25.05.2012

Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media
23.05.2012

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

- For NON-US Media Only
22.05.2012

One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

- For NON-US Media Only
22.05.2012

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK
21.05.2012

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK
29.04.2012

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only
24.04.2012

Boehringer Ingelheim on growth path - Successful 2011 financial year

20.04.2012

GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media
19.04.2012

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

- For media outside of the U.S.A. only